In-Patient Treatment of Fibromyalgia: A Controlled Nonrandomized Comparison of Conventional Medicine versus Integrative Medicine including Fasting Therapy
Table 2
Outcomes in both groups at baseline, week 2 and 12 with group differences as indicators of change.
Integrative medicine group
Rheumatology group
Mean diff
Mean diff (95% CI)
Baseline
Visit 2
Visit 3
Baseline
Visit 2
Visit 3
1-2 (95% CI)
value
1–3 (95% CI)
Value
FIQ score
−11.2 (−20.1, −2.3)
0.014
−6.7 (−17.5, 4.1)
0.223
Pain score
−17.5 (−28.8, −6.1)
0.003
−13.0 (−28.0, 2.1)
0.091
Quality of sleep
−15.5 (−30.6, −0.4)
0.044
16.5 (−30.0, −3.1)
0.016
HADS Anxiety
−2.9 (−4.6, −1.3)
<.001
−2.3 (−3.8, −0.9)
0.002
HADS Depression
−1.5 (−3.3, 0.3)
0.097
−2.0 (−4.0, −0.0)
0.046
SES Pain Perception
−10.1 (−14.7, −5.5)
<.001
−5.2 (−11.0, 0.5)
0.075
STAI State Score
−8.2 (−13.9, −2.4)
0.005
−6.1 (−11.8, −0.4)
0.036
STAI Trait Score
−8.3 (−12.3, −4.2)
<.001
−4.8 (−8.9, −0.7)
0.022
BfS Well-being
−6.8 (−12.5, −1.2)
0.018
−1.4 (−8.0, 5.2)
0.675
Values are mean SD if not indicated otherwise. SBP: systolic blood pressure; DBP: diastolic blood pressure. STAI: State and Trait Anxiety questionnaire, FIQ: Fibromyalgia impact questionnaire; HADS: Hospital Anxiety and Depression scale; 1-2 = difference between groups from baseline to visit 2 at 2 weeks, 1–3 = difference between groups from baseline to visit 3 at 12 weeks, values for between group difference of change, adjusted.
